Last reviewed · How we verify
NCT03369509: BdDAllergo
Allergic Versus Non Allergic Hypersensitivity Drug Reaction (BdDAllergo)
trial in Allergic Hypersensitivity Drug Reaction Versus Non-allergic Hypersensitivity Drug Reaction Cross Reaction in 456 participants. Terminated before completion.
1 August 2018
Quick facts
| Lead sponsor | University Hospital, Grenoble |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 456 |
| Start date | 29 May 2017 |
| Primary completion | 1 August 2018 |
| Estimated completion | 1 August 2018 |
| Sites | 1 location across France |
Conditions studied
- Allergic Hypersensitivity Drug Reaction Versus Non-allergic Hypersensitivity Drug Reaction Cross Reaction — all drugs for Allergic Hypersensitivity Drug Reaction Versus Non-allergic Hypersensitivity Drug Reaction Cross Reaction →
Sponsor
University Hospital, Grenoble
Who can join
18 and older, any sex, with Allergic Hypersensitivity Drug Reaction Versus Non-allergic Hypersensitivity Drug Reaction Cross Reaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The creation of a database containing the medical data of patients followed in allergology at the University Hospital of Grenoble will permit to study allergic versus non-allergic hypersensitivity drug reaction as well as the risk of cross-reactions between medicinal drugs belonging to the same pharmacological class. The main objectives of the study are to estimate and to compare the proportion of allergic hypersensitivity drug reaction and the proportion of non allergic hypersensitivity drug reaction, and to characterize these two types of hypersensitivity drug reaction on clinical, biological and chronological aspects. In a second time, ancillary study will be conducted in order to : * identify drugs that potentially induced histamine-liberation in patients diagnosed with non allergic hypersensitivity drug reaction * investigate the risk of cross-reactions between drugs belonging to the same pharmacotherapeutic class in patients diagnosed with allergic hypersensitivity drug reaction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03369509
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital, Grenoble trials
Trials by the same sponsor.
- NCT07479225 — Circulating Cell-Free DNA for Brain Abscess Diagnosis: A Pilot Study · NA · not yet recruiting
- NCT07477613 — Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke · NA · not yet recruiting
- NCT07379372 — Bladder Overactivity and Post-Botulinum Toxin Telemonitoring · NA · not yet recruiting
- NCT07166991 — Anesthesia sTrategy foR Organ Procurement In braiN dEath · Phase 3 · recruiting
- NCT07367880 — The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03369509 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Grenoble
- Last refreshed: 6 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03369509.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing